亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 三氟乙酰基三肽-2Cas: 64577-63-5
三氟乙酰基三肽-2Cas: 64577-63-5
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 10000g起訂1g
品牌 成都云希
CAS號 64577-63-5
純度 ≥98%
分子式 C21H28F3N3O6
過期 長期有效
更新 2021-07-05 16:42
 
詳細信息

1.Basic information:

INCI Name: Trifluoroacetyl Tripeptide-2

Synonym: ECM-Protect, Progeline

Cas No: 64577-63-5

Formula: C21H28F3N3O6

Molecular:475.47

Solubility: slightly soluble in water

Stability: stable

Odor: no

Grade: cosmetic

Source: synthetic

Formulation: available for your reference, please contact us.

COA and MSDS: available for your reference, please contact us.

Delivery: promptly from stock

Appearance: white powder

 

2.Usage: Trifluoroacetyl Tripeptide-2 reduces progerin synthesis, MMP and elastase inhibitor, increases syndecan, contracts collagen to reduce signs of aging including sagging and wrinkles

Description: Trifluoroacetyl Tripeptide-2 is a 3 amino acids peptide biomimetic of elafin that modulates progerin, a new senescence marker, for a *plete remodelling effect and reduction of the appearance of wrinkles.

 

3.Description: Trifluoroacetyl Tripeptide-2 Reduces progerin synthesis, MMP and elastase inhibitor, increases syndecan, contracts collagen to reduce signs of aging including sagging and wrinkles

 

4. Mechanism:

1. Tripeptide-2 Reduces progerin to a young cell level to delay cell senescence.

2. Tripeptide-2 Stimulates sirtuin production and activity to extend cell lifespan.

3. Tripeptide-2 Boosts collagen production and inhibits degradation enzymes activity(collagenase,elastase,MMP-1,MMP-3,MMP-9).

©2025 成都云希化工有限公司 版權所有   技術支持:化工網   訪問量:41585  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |